# Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Source: https://onco.cc/trials/nct06514027/  
OnCo record `nct06514027` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pemetrexed, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by BeBetter Med Inc, now recruiting.

## Summary

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations is a phase 2 interventional study registered as NCT06514027 by BeBetter Med Inc, with 30 participants planned, started 2024-08-28 and due to reach its primary completion in 2027-06. Interventions recorded: BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06514027
- Phase: 2
- Setting: A Multicenter, Open Phase II Clinical Study on the Safety and Efficacy of BEBT-109 Combined With Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- Sponsor: BeBetter Med Inc
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06514027: https://clinicaltrials.gov/study/NCT06514027

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [BeBetter Med](https://onco.cc/companies/bebetter-med/)

---
JSON: https://onco.cc/api/v1/entities/nct06514027.json